# A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

> **NCT00864760** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Gabapentin 800 mg tablets, single dose (1 tablet)
- **DRUG:** NEURONTIN® 400 mg capsules, single dose (2 capsules)

## Key facts

- **NCT ID:** NCT00864760
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 1999-06
- **Final completion:** 1999-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2010-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864760, "A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00864760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*